Leonardo Pozo Garcia1, Sandhya S Thomas1,2, Harsith Rajesh3, Sankar D Navaneethan1,2,4,5. 1. Section of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine. 2. Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center. 3. Katy ISD, Katy. 4. Veterans Affairs Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety, Houston. 5. Institute of Clinical and Translational Research Baylor College of Medicine, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Diabetic kidney disease is the most common cause of chronic kidney disease (CKD) and end-stage kidney disease in the world. Risk factor modification, glucose control, and renin-angiotensin-aldosterone system blockade have remained the standard of care for 2 decades. New therapeutic agents have emerged in recent years, demonstrating kidney and cardiovascular benefits, and herein we review recent clinical trials on this topic. RECENT FINDINGS: After the publication of several cardiovascular outcome trials for sodium-glucose cotransporter 2 inhibitors (SGLT-2i), new trials have focused ON primary kidney-specific outcomes demonstrating safety and benefits among patients with proteinuric CKD; patients with or without diabetes, and heart failure with preserved ejection fraction (HFpEF) respectively. Similarly, nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) and glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) have improved cardiovascular and kidney outcomes. Recently, clinical practice guidelines have also been updated to reflect this new evidence. SUMMARY: In summary, SGLT-2i, GLP-1 RAs, and ns-MRAs have demonstrated cardiovascular and kidney benefits, including all-cause and cardiovascular mortality, progression to end-stage kidney disease, and hospitalizations for heart failure exacerbation among diverse patient population.
PURPOSE OF REVIEW: Diabetic kidney disease is the most common cause of chronic kidney disease (CKD) and end-stage kidney disease in the world. Risk factor modification, glucose control, and renin-angiotensin-aldosterone system blockade have remained the standard of care for 2 decades. New therapeutic agents have emerged in recent years, demonstrating kidney and cardiovascular benefits, and herein we review recent clinical trials on this topic. RECENT FINDINGS: After the publication of several cardiovascular outcome trials for sodium-glucose cotransporter 2 inhibitors (SGLT-2i), new trials have focused ON primary kidney-specific outcomes demonstrating safety and benefits among patients with proteinuric CKD; patients with or without diabetes, and heart failure with preserved ejection fraction (HFpEF) respectively. Similarly, nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) and glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) have improved cardiovascular and kidney outcomes. Recently, clinical practice guidelines have also been updated to reflect this new evidence. SUMMARY: In summary, SGLT-2i, GLP-1 RAs, and ns-MRAs have demonstrated cardiovascular and kidney benefits, including all-cause and cardiovascular mortality, progression to end-stage kidney disease, and hospitalizations for heart failure exacerbation among diverse patient population.
Authors: Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2011-04-21 Impact factor: 10.121
Authors: Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Sankar D Navaneethan; Sophia Zoungas; M Luiza Caramori; Juliana C N Chan; Hiddo J L Heerspink; Clint Hurst; Adrian Liew; Erin D Michos; Wasiu A Olowu; Tami Sadusky; Nikhil Tandon; Katherine R Tuttle; Christoph Wanner; Katy G Wilkens; Lyubov Lytvyn; Jonathan C Craig; David J Tunnicliffe; Martin Howell; Marcello Tonelli; Michael Cheung; Amy Earley; Peter Rossing; Ian H de Boer; Kamlesh Khunti Journal: Ann Intern Med Date: 2020-11-10 Impact factor: 25.391
Authors: John B Buse; Robert R Henry; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron Journal: Diabetes Care Date: 2004-11 Impact factor: 19.112
Authors: George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope Journal: JAMA Date: 2015-09-01 Impact factor: 56.272
Authors: Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad Journal: Eur Heart J Date: 2013-05-27 Impact factor: 29.983